Literature DB >> 30858221

In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria.

Carolyn Shoen1, David Benaroch2, Mary Sklaney2, Michael Cynamon1.   

Abstract

The in vitro activity of omadacycline, a new tetracycline derivative, was evaluated against isolates of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum using a broth microtiter dilution assay. Omadacycline had MIC90 values of 2 μg/ml, 0.25 μg/ml, and 0.5 μg/ml, respectively. The in vitro activity of omadacycline against rapidly growing mycobacteria indicates that it may have the potential to improve therapy for infections caused by these organisms.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  antimicrobials; in vitrozzm321990; nontuberculous mycobacteria

Mesh:

Substances:

Year:  2019        PMID: 30858221      PMCID: PMC6496053          DOI: 10.1128/AAC.02522-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 2.  Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.

Authors:  S Ken Tanaka; Judith Steenbergen; Stephen Villano
Journal:  Bioorg Med Chem       Date:  2016-07-18       Impact factor: 3.641

3.  In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.

Authors:  A B Macone; B K Caruso; R G Leahy; J Donatelli; S Weir; M P Draper; S K Tanaka; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

4.  Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease.

Authors:  Joseph O Falkinham
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

  4 in total
  14 in total

1.  In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.

Authors:  Sanjay Singh; Tawanda Gumbo; Gunavanthi D Boorgula; Prem Shankar; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2022-08-17       Impact factor: 5.938

3.  Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series.

Authors:  Jeffrey C Pearson; Brandon Dionne; Aaron Richterman; Samuel J Vidal; Zoe Weiss; Gustavo E Velásquez; Francisco M Marty; Paul E Sax; Sigal Yawetz
Journal:  Open Forum Infect Dis       Date:  2020-09-09       Impact factor: 3.835

4.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

Review 6.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

7.  Microbiology and Preclinical Review of Omadacycline.

Authors:  James A Karlowsky; Judith Steenbergen; George G Zhanel
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

8.  Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.

Authors:  Hannelore I Bax; Corné P de Vogel; Johan W Mouton; Jurriaan E M de Steenwinkel
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

9.  Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease.

Authors:  Jianhui Chen; Lan Zhao; Yanhua Mao; Meiping Ye; Qi Guo; Yongjie Zhang; Liyun Xu; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

Review 10.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.